Welcome to the Neuroendocrine Tumor Center of Excellence—the only Center of Excellence in the United States and one of only 50 worldwide. In 2019, the European Neuroendocrine Tumor Society (ENETS) conferred this honor on the University of Iowa in recognition of the Holden Comprehensive Cancer Center’s (HCCC) advanced interdisciplinary approach to diagnosing neuroendocrine tumor (NET) in people, the quality and breadth of the multidisciplinary team’s medical treatments for NETs, and the institution’s continuity of care for people with NETs.
Thomas O’Dorisio, MD, Emeritus Professor of Internal Medicine, and M. Sue O’Dorisio, MD, PhD, Professor of Pediatrics, began their quest in 2000 to bring new NET diagnostic methods, treatments, and research cores to address the significantly rising incidence of these slow-growing but relentless cancers. Their initial efforts led to the first-of-its-kind grant. In 2015, the HCCC received a Specialized Programs of Research Excellence (SPORE) grant to study the prevention, detection, diagnosis, and treatment of NETs—the only SPORE grant ever awarded for the study of NETs.
Joseph Dillon, MB, BCh, BAO, Professor of Internal Medicine, serves as Quality Control Director for the Center. Dr. Dillon’s role is to assess the effectiveness of each of the component disciplines of the Center of Excellence in their treatment of people with NETS.
Researchers, physicians, and patients are all invited to contact our team for collaborations, treatment networking, and patient clinical trial enrollment.
Learn more:
https://cancer.uiowa.edu/cancer-types/neuroendocrine-cancer
https://medicine.uiowa.edu/net-spore